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ABSTRACT    25 
Although vascular endothelial growth factor (VEGF) inhibitors (VEGFIs), are effective anti-26 
cancer therapies, they cause hypertension through unknown mechanisms. We questioned 27 
whether changes in vascular redox state may be important, since VEGF signaling involves nitric 28 
oxide (NO) and reactive oxygen species (ROS). Molecular mechanisms, including NOS, Nox-29 
derived ROS, anti-oxidant systems and vasoconstrictor signaling pathways, were probed in 30 
human endothelial cells (EC) and vascular smooth muscle (hVSMC) exposed to vatalanib, a 31 
VEGFI. Vascular functional effects of VEGFI were assessed ex vivo in mouse arteries. 32 
Cardiovascular and renal in vivo effects were studied in vatalanib- or gefitinib (epidermal growth 33 
factor inhibitor (EGFI))-treated mice. In ECs, vatalanib decreased eNOS (Ser1177) 34 
phosphorylation and reduced NO and H2O2 production, responses associated with increased 35 
Nox-derived O2
- and ONOO- formation. Inhibition of Nox1/4(GKT137831) or Nox1 (NoxA1ds), 36 
prevented vatalanib-induced effects. Nrf2 nuclear translocation and expression of Nrf-2-37 
regulated anti-oxidant enzymes were variably downregulated by vatalanib. In hVSMCs, VEGFI 38 
increased Nox activity and stimulated Ca2+ influx and MLC20 phosphorylation. Acetylcholine-39 
induced vasodilatation was impaired and U46619-induced vasoconstriction was enhanced by 40 
vatalanib, effects normalized by N-acetyl-cysteine and worsened by L-NAME. In vatalanib-, but 41 
not gefitinib-treated mice vasorelaxation was reduced and media:lumen ratio of mesenteric 42 
arteries was increased with associated increased cardiovascular and renal oxidative stress, 43 
decreased Nrf-2 activity and downregulation of anti-oxidant genes. We demonstrate that 44 
inhibition of VEGF signaling induces vascular dysfunction through redox-sensitive processes. 45 
Our findings identify Noxs and antioxidant enzymes as novel targets underling VEGFI-induced 46 
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vascular dysfunction. These molecular processes may contribute to vascular toxicity and 47 
hypertension in VEGFI-treated patients. 48 
 49 
Keywords: Vascular endothelial growth factor, cancer, oxidative stress, vascular function, 50 
endothelial cells.   51 
 52 
INTRODUCTION 53 
Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is critical in 54 
solid tumour growth and metastasis. This process is regulated by growth factors of which 55 
vascular endothelial growth factor (VEGF) plays a key role through effects on endothelial cell 56 
(EC) and vascular smooth muscle cell (VSMC) function 1. The VEGF gene undergoes alternative 57 
splicing to form 6 isoforms, of which VEGF-A is the most biologically active 2, 3. VEGF-A binds 58 
to two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGF receptor-2 (VEGFR-2 or Flk-1) 59 
and a non-tyrosine kinase, neuropilin (NRP1 and NRP2). However VEGFR-2 is the primary 60 
receptor through which VEGF signals to regulate angiogenesis and endothelial function 2, 4. 61 
Binding to VEGFR-2 initiates a tyrosine kinase signaling cascade that promotes vasodilatation 62 
via nitric oxide (NO) and prostacyclins, cell proliferation/survival, migration and differentiation 63 
into mature blood vessels 5, 6.  64 
Inhibition of angiogenesis, by targeting VEGF signaling, has revolutionized cancer 65 
therapy with improved outcomes in some previously untreatable cancers. However clinical 66 
observations unexpectedly showed that VEGF inhibition (VEGFI) was associated with 67 
cardiovascular toxicity, especially hypertension 7, 8. The magnitude of VEGFI-induced 68 
hypertension is significant, with almost every clinical trial of VEGF inhibitors (VEGFIs) 69 
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reporting an increase in blood pressure (BP) as an adverse effect with 40-60% of patients 70 
developing hypertension often severe (>150/100 mmHg) or hypertensive crisis 9-12. Hypertension 71 
develops acutely, within 24 hours of starting treatment, and by 6 days it is sustained 13. Upon 72 
treatment cessation BP decreases 9, 10, 14. 73 
The pathophysiology of VEGFI-induced hypertension is elusive, although endothelial 74 
dysfunction, vascular remodeling and capillary rarefaction have been implicated 2, 15. VEGF is a 75 
known vasodilator through its effects on NO and as such a potential consequence of VEGFI is 76 
reduced NO, impaired vasodilatation and increased vascular tone, important determinants of 77 
augmented vascular resistance and BP elevation 16-18. However clinical and experimental data are 78 
conflicting, with studies showing both increased and decreased eNOS activity and NO 79 
production 16, 17. Additionally, recent findings demonstrated endothelial-independent processes 80 
are involved in VEGFI effects 19. Increased levels of ET-1, activation of the renin-angiotensin 81 
system (RAS), EC apoptosis and rarefaction have also been implicated in VEGFI-induced 82 
hypertension 17, 18.  83 
Oxidative stress may contribute to the development of hypertension during anti-84 
angiogenic therapy. Recent evidence indicates that superoxide anion (O2
-) and hydrogen 85 
peroxide (H2O2) play a role in VEGF/VEGFR signaling and angiogenesis 
20, 21. NADPH oxidase 86 
(Nox) isoforms are primarily responsible for vascular ROS generation in rodent (Nox1,2,4) and 87 
human vascular cells (Nox1,4,5)  with Nox4 generating mainly H2O2 and Nox1, 2 and 5 88 
generating O2- 
22, 23. VEGF also regulates expression and activity of antioxidant system, 89 
including superoxide dismutase (SOD) and nuclear factor erythroid 2–related factor 2 (Nrf-2), 90 
the master regulator of antioxidant enzyme transcription 24, 25. Thus, in addition to VEGF 91 
inducing vasodilatation through NO, generation of H2O2 through Nox4 and activation of 92 
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antioxidants, may influence vasorelaxation. However, whether VEGFI impacts these redox-93 
sensitive processes to modulate a hypertensive vascular phenotype with associated BP elevation 94 
is unclear. Here we hypothesized that VEGFIs promote oxidative stress leading to impaired 95 
vasodilatation and hypercontractility, processes associated with BP elevation. Mechanisms 96 
underlying this may relate to Nox dysregulation, downregulation of Nrf-2 -regulated antioxidant 97 
systems and altered Ca2+ handling in vascular cells.  98 
 99 
METHODS  100 
The authors declare that all supporting data are available within the online supplementary files 101 
(Please see http://hyper.ahajournals.org. for expanded Methods section). 102 
 103 
All experimental protocols on mice were performed in accordance with the Ethical Principles in 104 
Animal Experimentation adopted by the West of Scotland Research Ethics Service and in 105 
accordance with the National Institutes of Health Guide for the Care and Use of Laboratory 106 
Animals. Studies at Sapienza University were conducted in accordance with the Italian Law on 107 
the Protection of Animals. Human vascular smooth muscle cells were isolated from surgical 108 
specimens and in accordance with protocols approved by the West of Scotland Research Ethics 109 
Service (WS/12/0294). 110 
Experimental models 111 
Studies were performed at the cellular (human ECs, VSMCs), tissue (isolated mouse arteries) 112 
and whole animal (VEGFI-treated mice) levels. We examined effects of a VEGFR inhibitor, 113 
vatalanib and in some experiments compared effects to gefitinib, an inhibitor of the epidermal 114 
growth factor receptor (EGFR). We used this comparator agent because VEGF and EGF signal 115 
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through similar pathways, yet whereas VEGF inhibition causes hypertension, EGFR inhibition 116 
does not.   117 
 118 
Cell culture. Cell-based studies were performed in human aortic endothelial cell (HAEC) and 119 
primary culture vascular smooth muscle cells (hVSMC).  120 
Mice. Ex vivo vascular studies. In some experiments, mouse mesenteric arteries were isolated to 121 
assess vascular functional responses to vatalanib in the absence and presence of L-NAME 122 
(eNOS inhibitor) or N-acetyl-cysteine ((NAC) ROS scavenger). In vivo studies: Three groups of 123 
male SV-129 mice were studied for 2 weeks): 1) vehicle-treated group; 2) VEGFR inhibitor, 124 
vatalanib-treated group (Vat, 100 mg/Kg/day), and 3) EGFR inhibitor, gefitinib-treated group 125 
(Gef, 100 mg/Kg/day).  126 
Experimental protocols 127 
Vascular levels of NO, O2
-, H2O2 and nitrotyrosine and Nox activity were assessed by 128 
fluorescence, chemiluminescence and amplex red assays. VSMC [Ca2+]i was measured by Cal-129 
520 fluorescence. 130 
Nrf-2 activity was assessed by nuclear translocation and Keap-1 expression by immunoblotting. 131 
Anti-oxidant enzymes (catalase activity) and gene expression (SOD1, catalase, GPX1, HO1) 132 
were determined by activity assays and qPCR. 133 
Phosphorylation of eNOS and MLC20 was determined by immunoblotting. 134 
Vascular functional and structural properties were assessed by wire and pressure myography. 135 
Statistical analysis 136 
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Statistical analysis was performed using GraphPad Prism 3.0 (GraphPad Software Inc., San 137 
Diego, CA, USA). Data are presented as means±standard error of the mean (SEM). Groups were 138 
compared using student's t test or one-way analysis of variance (ANOVA). Bonferroni or 139 
Tukey's post-test were used as appropriate. Results of statistical tests with p<0.05 were 140 
considered significant. 141 
RESULTS 142 
Vatalanib influences ROS and NO generation in human endothelial cells  143 
Vatalanib increased NADPH-dependent O2
- generation in HAECs, effects that were inhibited by 144 
GKT137831 and NoxA1dstat (figure 1A). This was associated with increased p47phox 145 
membrane expression (figure 1B), reduced generation of H2O2 and NO and increased formation 146 
of ONOO- (figures 1C, 1D, S1). In vatalanib-treated cells, phosphorylation of eNOS (active site, 147 
Ser1177) was reduced (figure S1). Vatalanib, at 24 hours, influenced expression of endothelial 148 
cell Noxs, which are responsible for O2
- production. In particular vatalanib decreased expression 149 
of Nox4 and increased expression of Nox5 (figure 2A, 2B), without significantly influencing 150 
Nox1 (figure S2). Nuclear accumulation of Nrf2 and gene expression of Nrf-2-regulated anti-151 
oxidant genes, catalase, GPX1 and HO1, but not SOD1, was downregulated 8 hours after 152 
vatalanib treatment (figure 1E, 2C-F). Gefitinib does not alter O2
- production neither modulates 153 
Noxs and anti-oxidants mRNA levels in vascular cells (figure S6). 154 
Vatalanib increases ROS generation and modulates pro-contractile signaling in human 155 
vascular smooth muscle cells  156 
Vatalanib increased O2
- production and ONOO- levels in hVSMC (figure 1F, S1). Pretreatment 157 
with Nox1/4 inhibitors prevented vatalanib-induced ROS generation. VEGF inhibition induced a 158 
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significant increase in Ca2+ influx in hVSMCs, effects that were attenuated by N-acetyl-l-159 
cysteine (NAC) (figure 3E). Vatalanib also influenced pro-contractile signaling pathways, by 160 
inducing phosphorylation of MLC20, critically involved in triggering vascular contraction (figure 161 
3D).   162 
Vascular dysfunction induced by vatalanib is mediated by NOS- and redox-sensitive 163 
mechanisms  164 
To evaluate whether vatalanib-induced effects observed at the cellular level have functional 165 
significance at the vascular level, we studied isolated mouse mesenteric resistance arteries by 166 
myography and exposed vessel segments to vatalanib in the absence and presence of NOS 167 
inhibitors and ROS scavengers. As shown in figure 3A, ACh induced almost 100% 168 
vasorelaxation in control vessels, whereas in vatalanib-treated vessels, ACh-mediated 169 
vasorelaxation was reduced, with arteries relaxing maximally  40%. These responses were 170 
worsened by L-NAME, a NOS inhibitor. In arteries pre-treated with NAC, vatalanib-induced 171 
endothelial dysfunction was ameliorated (figure 3B). Corroborating our findings in hVSMC, 172 
vatalanib amplified agonist (U46619)-induced vasoconstriction, an effect blocked by NAC 173 
(figure 3C). 174 
Systemic oxidative stress, vascular dysfunction and arterial remodeling in vatalanib-175 
treated mice.  176 
To further explore whether vatalanib influences redox-sensitive processes and vascular function 177 
in vivo, we examined mice treated with vatalanib for 2 weeks, and compared effects to gefitinib, 178 
an EGFR inhibitor. At the doses used, mean blood pressure was not significantly different in 179 
control (92.6±1.7 mmHg), vatalanib-treated (91.2±1.8 mmHg) and gefitinib-treated groups 180 
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(88.0±2.5 mmhg). Vatalanib increased systemic ROS generation, as indicated by elevated 181 
plasma TBARS levels in the vatalanib (9.0±2.0 µmol/l) versus vehicle (5.1±0.2 µmol/l) and 182 
gefitinib groups (5.2±0.5 µmol/l).  183 
As shown in figure 4A and supplemental table S1, ACh-induced maximal vasorelaxation 184 
and EC50 of isolated small mesenteric arteries were blunted in vatalanib- but not gefitinib-treated 185 
mice. SNP-induced vasodilatation was not influenced by either agent (figure 4B). Mesenteric 186 
arteries from vatalanib-treated mice also exhibited an increase in media-to-lumen ratio indicating 187 
vascular remodeling (figure S3). Vatalanib had no effect on cross-sectional area (CSA) (figure 188 
S3). Gefitinib did not significantly influence vascular function or structure.  189 
Vatalanib modulates redox signaling in tissues from mice  190 
To determine whether VEGFIs influence redox status in cardiovascular and renal tissue, we 191 
assessed levels of H2O2, O2- and ONOO
-, catalase activity and expression of pro-oxidant 192 
oxidases and anti-oxidant enzymes in aorta, kidney and heart in VEGFI- treated mice. 193 
 As shown in figure 4 aortic and cardiac levels of H2O2 were reduced, while ONOO
- 194 
levels were increased. Catalase activity was increased in aorta in the vatalanib group. Gene 195 
expression of Nox1, but not Nox2 or Nox4, was significantly increased in the heart by vatalanib 196 
and gefitinib (figure S4). Cardiac gene expression of anti-oxidant enzymes catalase and GPX1 197 
was reduced in vatalanib-treated mice, without effect on SOD1 (figure S4). 198 
NADPH-stimulated production of O2
- and H2O2 levels were augmented by vatalanib in 199 
kidneys (figures 5A, 5B). This was associated with decreased activity of renal catalase (figure 200 
5C) and downregulation of the master anti-oxidant transcription factor Nrf2, indicated by 201 
decreased Nrf2 nuclear translocation and increased cytosolic levels of the Nrf2 repressor, Keap-1 202 
(figures 5D, 5E). At the gene level, expression of anti-oxidant enzymes catalase and GPX1 203 
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(figures 5F), but not SOD1, was reduced in treated mice (figure S5). Vatalanib decreased 204 
mRNA expression of Nox4, without effect on Nox1 and Nox2 (figure S5). 205 
 206 
DISCUSSION 207 
Despite the anti-angiogenic and anti-cancer benefits of VEGF inhibitors in clinical medicine, 208 
these agents have potent vascular toxicities and are pro-hypertensive due to, as yet, unclear 209 
molecular mechanisms. Processes that have been implicated include reduced endothelial-derived 210 
NO production, increased ET-1 levels, activation of the renin-angiotensin system, endothelial 211 
cell apoptosis and microvascular rarefaction 26 16 17. Here we advance the field by demonstrating 212 
an important role for oxidative stress. In particular, we show that vatalanib, a VEGFR inhibitor, 213 
increased vascular cell ROS production and ONOO- formation and decreased activation of the 214 
eNOS-NO pathway. These phenomena translated to endothelial dysfunction, vascular 215 
hypercontractility and cardiovascular and renal oxidative stress in VEGFI-treated mice. Potential 216 
mechanisms underlying these effects involve upregulation of Noxs, in an isoform- and tissue-217 
specific manner, and downregulation of Nrf2-regulated anti-oxidant genes.  218 
Endothelial function and vascular integrity are regulated by VEGF/VEGFR, through multiple 219 
signaling pathways, including PI3K-NOS and protein tyrosine phosphatases (PTP), which are 220 
modulated by changes in redox state. In particular VEGF-induced activation of NOS and PTPs is 221 
linked to a reduced oxidative milieu that maintains vascular health 20, 21, 27, 28. In addition, 222 
signaling through VEGF protects cells from oxidative stress, in part through activation of Nrf2-223 
regulated antioxidant enzymes 29, 30. Disruption of these protective systems by inhibiting VEGF 224 
signaling leads to oxidative stress and cell damage. We explored this concept in the context of 225 
VEGFI-induced vascular toxicity and investigated whether vatalanib, a VEGFR inhibitor, 226 
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influences redox state in human endothelial and vascular smooth muscle cells. Since we were 227 
particularly interested in the direct cellular effects of VEGFI, recapitulating the clinical scenario 228 
of anti-angiogenic therapy, our studies were conducted without adding exogenous VEGF. Both 229 
endothelial cells and VSMCs exhibited increased vatalanib-induced NADPH-stimulated O2
- 230 
production, involving Nox1/Nox4. Since ROS generation was rapid, it is likely that 231 
constitutively functional Nox1/4 was modulated by vatalanib, which also had more long-term 232 
actions by regulating Nox gene expression in an isoform-specific manner. The acute effect may 233 
also relate to dampening of protective anti-oxidant systems by vatalanib, similar to what has 234 
been shown for other VEGFIs 31, 32. In ECs, a consequence of increased O2
- production is 235 
decreased eNOS-generated NO bioavailability and increased ONOO- formation, as we observed. 236 
These events, together with reduced generation of H2O2, which induces vasodilation and is 237 
vasoprotective 33, 34, may underlie endothelial dysfunction and vascular oxidative damage by 238 
vatalanib. In support of our findings, others have shown that VEGFIs acutely increase ROS 239 
generation in retinal pigment epithelial cells 29, increase oxidative cellular toxicity 35 and 240 
augment oxidative stress, inflammation and endothelial dysfunction in mouse lung and human 241 
lung microvascular endothelial cells 36.  242 
To investigate whether the findings observed at the cellular level translate to functional 243 
responses, we studied mouse vessels exposed to vatalanib ex vivo, and demonstrated significantly 244 
impaired endothelial function, responses that likely involve dysregulated eNOS and oxidative 245 
stress because L-NAME worsened vasorelaxation, whereas the ROS scavenger NAC, 246 
ameliorated endothelium-dependent vasorelaxation.Vatalanib also amplified agonist-stimulated 247 
vasoconstriction, possibly linked to increased [Ca2+]i signaling and activation of contractile 248 
machinery, as evidenced by increased phosphorylation of MLC as we demonstrated in VSMCs. 249 
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Since NAC normalized hypercontractile responses, redox-sensitive processes are likely also 250 
important in vatalanib vascular functional effects. In line with our findings, four multi-targeted 251 
VEGFIs potently increased vasoconstriction in mice 19.  252 
The findings in isolated arteries were recapitulated in in vivo studies in mice treated for 2 253 
weeks with vatalanib, where endothelium-dependent vasorelaxation was attenuated with 254 
associated increased cardiovascular production of O2
- and ONOO- and reduced generation of 255 
H2O2. Whereas O2
- and ONOO- are associated with vasoconstriction and vascular injury, H2O2 is 256 
vasoprotective acting as a vasodilator through protein kinase G (PKG) 33, 34, 37. Processes 257 
underlying these phenomena likely involve decreased eNOS/NO generation, Nox activation, 258 
increased catalase activity (which catalyzes the decomposition of H2O2 to H2O and O2) and 259 
reduced protective anti-oxidant systems, similar to what we observed in human vascular cells.  260 
Whereas vatalanib reduced H2O2 production in vessels, it increased production in 261 
kidneys, possibly due to reduced catalase activity. Renal oxidative stress was increased by 262 
vatalanib, with associated decreased activity of Nrf2 as evidenced by decreased nuclear 263 
translocation and increased cytosolic content of the Nrf2 repressor Keap-1. Loss of Nrf2 activity, 264 
which regulates anti-oxidant genes, such as catalase and GPX1, likely dampens the antioxidant 265 
protective status, contributing to renal oxidative stress in vatalanib-treated mice. Interplay 266 
between VEGF, Nrf2 and other antioxidant systems has been demonstrated 58,59 and a VEGF-267 
Nrf2 positive feedback loop, which protects against oxidative stress, has been demonstrated in 268 
brain microvascular endothelial cells 38 and in cancer cell lines 30. Hence disruption of this 269 
feedback loop with VEGFIs, would downregulate Nrf2, similar to what we observed in our 270 
studies. Aggravation of renal damage by VEGFIs has also been shown in diabetic mice, 271 
processes attributed to oxidative stress and inactivation of the Akt/eNOS/NO axis 39.  272 
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To elucidate whether inhibition of VEGFR tyrosine kinases by vatalanib is a generalized 273 
or specific phenomenon, we also evaluated effects of gefitinib, which inhibits EGFR, in part, 274 
through common VEGFR signaling pathways. Our findings clearly demonstrate that vatalanib, 275 
but not gefitinib induced vascular dysfunction and cardiovascular and renal oxidative stress, 276 
suggesting specific cardiovascular toxicity when VEGFR is targeted. Others have also shown 277 
differential effects of VEGFI and EGFIs 28,29. Mice treated with sunitinib, which primarily 278 
targets VEGFR tyrosine kinases, exhibited systolic dysfunction and metabolic abnormalities, 279 
which were absent in mice treated with the EGFRI erlotinib 40. Using a non-targeted 280 
metabolomics approach, it was found that sunitinib, but not erlotinib, decreased docosahexaenoic 281 
acid (DHA), arachidonic acid (AA)/ eicosapentaenoic acid (EPA), O-phosphocolamine, and 6-282 
hydroxynicotinic acid, important anti-inflammatory mediators and regulators of mitochondrial 283 
function. Loss of these compounds may underlie VEGFI-induced mitochondrial dysfunction, 284 
oxidative stress and cardiovascular damage 40. 285 
Despite the vascular dysfunction, arterial remodelling and significant cardiovascular and 286 
renal oxidative effects induced by vatalanib, mice did not develop hypertension. Reasons for this 287 
may relate to the low dose of vatalanib used and/or to the relatively short treatment period. In 288 
addition, we used tail cuff methodology to measure blood pressure at one time point, and as such 289 
we may have missed subtle changes in blood pressure, especially over the 24-hour period. 290 
Telemetry would have provided a better approach to fully characterise blood pressure changes. 291 
Nevertheless, our data clearly demonstrate, that even at sub-pressor doses, vatalanib induced 292 
cardiovascular and renal toxicity, which may be amplified with higher doses and more chronic 293 
treatment 39. 294 
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In conclusion, this study provides novel mechanistic insights to better understand the 295 
pathophysiology of VEGFI-induced vascular dysfunction and hypertension. In particular, we 296 
demonstrate at the cellular, vascular and whole animal levels, that vatalanib promotes oxidative 297 
stress, Nox dysregulation and downregulation of Nrf2-regulated antioxidant systems. Our study 298 
identifies redox-sensitive mechanisms whereby VEGF signaling inhibition may cause 299 
cardiovascular toxicity, as highlighted in figure 6. This study might be especially important to 300 
guide new therapeutic approaches to reduce cardiovascular risk without compromising anti-301 
cancer benefit of VEGFIs. Such an approach may include strategies to reduce VEGFI-induced 302 
oxidative stress using adjuvant therapies such as Nrf2 activators or Nox inhibitors. This concept 303 
awaits further confirmation.   304 
PERSPECTIVES  305 
Our results identify novel molecular mechanisms involving changes in redox state whereby 306 
VEGFI promotes vascular injury and dysfunction. Our data are of clinical significance because 307 
these processes may contribute to vascular toxicities associated with VEGFI-associated 308 
hypertension in patients treated with anti-angiogenic therapy targeting VEGF signaling 309 
pathways. In particular our findings that VEGFI-indiced oxidative stress is linked to upregulation 310 
of vascular Noxs and dampening of anti-oxidant enzymes may direct future therapeutic 311 
approaches to reduce vascular toxicities caused by VEGFI anti-cancer drugs. For example, 312 
adjuvant therapy with Nrf2 agonists may be an interesting approach, that might warrant further 313 
consideration. 314 
 315 
 316 
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NOVELTY AND SIGNIFICANCE  464 
What Is New? 465 
This study demonstrates that vatalanib, a VEGFR inhibitor, promotes oxidative stress by 466 
upregulating Noxs and inhibiting Nrf-2-regulated anti-oxidant systems. These processes 467 
contribute to VEGFI-induced vascular dysfunction. 468 
What Is Relevant? 469 
 Molecular mechanisms underlying VEGFI-induced vascular toxicity and hypertension are 470 
unclear, but oxidative stress may be important. 471 
 Modulating redox-sensitive targets of VEGFIs may ameliorate vascular dysfunction and 472 
injury associated with anti-angiogenic therapy. 473 
 Inhibiting oxidative stress by decreasing Nox activity or activating Nrf-2-regulated anti-474 
oxidant systems during VEGFI treatment may prevent cardiovascular risk and hypertension, 475 
without compromising anti-cancer therapy.  476 
 477 
Summary 478 
We identify novel molecular mechanisms involving redox-dependent processes whereby 479 
VEGFIs cause endothelial dysfunction and vascular injury. In particular, we demonstrate at the 480 
cellular, vascular and whole animal levels, that the VEGFI vatalanib promotes oxidative stress, 481 
Nox dysregulation and downregulation of Nrf2-regulated antioxidant systems. These processes 482 
may play a role in vascular toxicity and hypertension in patients treated with VEGFI anti-483 
angiogenic therapy. 484 
 485 
  486 
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FIGURE LEGENDS 487 
Figure 1. Vatalanib influences ROS and NO generation and modulates pro-contractile 488 
signaling in human vascular cells. (A) Lucigenin-derived chemiluminescence was performed 489 
in HAEC stimulated with vehicle or vatalanib in the presence or absence of NoxA1ds or 490 
GKT137831. (B) p47 phox membrane expression was assessed by western blotting in HAEC in 491 
presence of vatalanib or vehicle. (C) H2O2 levels, measured by amplex red in HAEC exposed to 492 
vatalanib. (D) NO levels were determined by DAF-FM in vatalanib-treated HAEC (5 minutes) in 493 
the presence or absence of GKT137831 or NoxA1ds (30 minutes). (E) Nuclear accumulation of 494 
Nrf2 was determined by ELISA in HAEC nuclear extracts. (F) Lucigenin-derived 495 
chemiluminescence was performed in hVSMC stimulated with vehicle or vatalanibNoxA1ds or 496 
GKT137831. Results from amplex red, lucigenin and DAF-FM assays were normalized by 497 
protein content. Results are means±SEM of 4 to 7 experiments. *p<0.05 vs. control; # vs. 498 
vatalanib. 499 
Figure 2. Expression of pro-oxidant (Noxs) and anti-oxidant systems in human vascular 500 
cells is modulated by vatalanib. mRNA expression of the Nox isoforms Nox4 (A), Nox5 (B),  501 
and the anti-oxidant genes catalase (C), GPX1 (D), HO1 (E) and SOD1 (F)  was determined by 502 
real time PCR in HAECs. PCR values were normalized by GAPDH mRNA expression. Results 503 
are mean±SEM of 4-6 experiments. *p<0.05 vs. control. 504 
Figure 3. Vascular dysfunction induced by vatalanib is mediated through mechanisms 505 
involving oxidative stress and downregulation of eNOS. Endothelium-intact mesenteric 506 
resistance arteries from wild type mice were incubated with vatalanib (100 nmol/L) or vehicle 507 
for 30 min. Relaxation responses of Phe-contracted vessels to ACh was evaluated in the absence 508 
and presence of (A) L-NAME (eNOS inhibitor, 100 µmol/L) or (B) N-acetyl-cysteine ((NAC), 509 
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ROS scavenger, 10 µmol/L) was added 30 min before vehicle or vatalanib addition. (C) 510 
Contraction curves to U46619 in the absence or presence of NAC. (D) Phosphorylation of 511 
MLC20 (Thr
18/Ser19) was determined byimmunoblotting in hVSMC stimulated with vatalanib 512 
(100 nmol/L); values were normalized by α-tubulin expression. (E) Ca2+ influx was assessed in 513 
hVSMC exposed to vatalanib  NAC. Area under the curve (AUC) indicates global Ca2+ influx 514 
in hVSMC. Results are mean±SEM of 3-6 experiments. *p<0.05 vs. vehicle; # p<0.05 vs. 515 
vatalanib; ⱷ p<0.05 vs. L-NAME.  516 
Figure 4. Vatalanib, but not gefitinib, impairs ACh-induced vasodilation and modulates 517 
redox signaling in aorta and heart from mice. Bar graphs represent the maximal response 518 
(Emax) of ACh (A) and SNP (B) in mesenteric arteries from mice treated with vatalanib (100 519 
mg/Kg/day), gefitinib (100 mg/Kg/day) or vehicle assessed by wire myograph. H2O2 levels were 520 
measured by amplex red assay in endothelium-intact aorta and heart (C) from vatalanib and 521 
gefitinib-treated mice. Nitrotyrosine was assessed as an index of peroxynitrite (ONOO-) 522 
formation in aorta and heart (D) from treated mice. Catalase activity was performed in aorta and 523 
heart E) by assay kit. Results were normalized by protein content. Results represent the 524 
mean±SEM of 5-7 experiments. *p<0.05 vs. vehicle. 525 
Figure 5. Renal oxidative and anti-oxidant effects of vatalanib.  (A) NADPH-stimulated O2
- 526 
production, assessed by lucigenin assay, in kidneys from vatalanib and gefitinib-treated mice. 527 
(B) H2O2 levels and catalase activity (C) measured by amplex red assay in kidneys. (D) Nuclear 528 
accumulation of Nrf2 was determined by ELISA in kidney nuclear extracts and (E) cytosolic 529 
Keap-1 cytosolic protein expression was evaluated by immunoblotting. (F) mRNA expression of 530 
Nrf2-regulated genes  (catalase, GPX1) was determined by real time PCR. PCR values were 531 
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normalized by GAPDH mRNA expression and Keap-1 values were normalized by α-tubulin 532 
protein expression. Results are mean±SEM of 5-7 experiments. *p<0.05 vs. vehicle. 533 
Figure 6. Putative mechanisms involving redox-sensitive processes whereby VEGF/VEGFR 534 
inhibition impacts vascular smooth muscle and endothelial cell function. VEGF inhibition 535 
by vatalanib in hVSMC (left panel) causes an increase in ROS generation through Nox1 and 4 536 
activation which is involved in pro-contractile signaling, such as increased [Ca2+]i and activation 537 
of MLC20, leading to enhanced vascular contraction. In endothelial cells (right panel), vatalanib 538 
acts by increasing ROS production through Nox activation but also by downregulating the 539 
antioxidant system. In addition, vatalanib decreases the vasodilatory ROS, H2O2, as well as 540 
reduces eNOS phosphorylation and NO production in endothelial cells, which may be 541 
culminating in endothelial dysfunction. The dysregulation of both vascular smooth muscle and 542 
endothelial cell function induced by vatalanib may induce vascular tone alterations and vascular 543 
remodeling, and may explain, at least in part, molecular mechanisms underlying VEGFI-544 
associated hypertension. 545 






